Overall rank by patents
#49,611
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Prometic Biotherapeutics, Inc.
USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, active 2019–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
5
Total patents granted
4
CPC technology areas
21.4
Avg claims per patent
+300%
5-year filing velocity
The verdict
Prometic holds 5 US patents across 4 technology areas, rank #49,611 of 50,000 tracked assignees.
- #49,611
- of 50,000 US assignees by volume
- Top 47%
- by Innovation Score (36.1/100)
- 21.4
- avg claims per patent
- +300%
- filing velocity, last 5 yrs
Portfolio overview
Prometic Biotherapeutics, Inc. has been granted 5 US utility patents between 2019 and 2023, placing Prometic Biotherapeutics, Inc. at rank #49,611 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Prometic Biotherapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Prometic sits between Prokarma, Inc. (5 patents, rank #49,607) and Proterrgo Inc. (5 patents, rank #49,615) - the closest US assignees by grant volume. The composite Innovation Score of 36.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 1 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Prometic Biotherapeutics, Inc.'s 21.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Prometic Biotherapeutics, Inc. against peers pursuing similar technology classes.
Who files at Prometic's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Prokarma
PROKARMA, INC.
5 patents
- Prolec GE Interna…
PROLEC GE INTERNACIONAL, S. DE. R. L. DE C.V.
5 patents
- Promau S R L
PROMAU S.R.L.
5 patents
- Promeco
PROMECO NV
5 patents
- Promise Technology
PROMISE TECHNOLOGY, INC.
5 patents
- Pronk
PRONK TECHNOLOGIES, INC.
5 patents
- Propst Family Par…
PROPST FAMILY LIMITED PARTNERSHIP
5 patents
- Proterrgo
PROTERRGO INC.
5 patents
- Prometic Biothera… ◀
PROMETIC BIOTHERAPEUTICS, INC.
5 patents
What this shows Prometic holds 5 patents at rank #49,611, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Prometic
By rank, the assignees closest to #49,611 in granted patent volume.
- Prokarma, Inc. #49,607 · 5 patents
- Prolec GE Internacional, S. DE. R. L. DE C.v. #49,608 · 5 patents
- Promau S.r.l. #49,609 · 5 patents
- Promeco Nv #49,610 · 5 patents
- Promise Technology, Inc. #49,612 · 5 patents
- Pronk Technologies, Inc. #49,613 · 5 patents
- Propst Family Limited Partnership #49,614 · 5 patents
- Proterrgo Inc. #49,615 · 5 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Prometic's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Prometic's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
36 Top 47% higher than 53% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2021 | 1 | 20.0% |
| 2022 | 1 | 20.0% |
| 2023 | 2 | 40.0% |
Which technologies does Prometic Biotherapeutics, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Prometic Biotherapeutics, Inc. hold?
Prometic Biotherapeutics, Inc. holds 5 US granted patents filed between 2019 and 2023, spanning 4 technology areas.
What is Prometic Biotherapeutics, Inc.'s Innovation Score?
Prometic Biotherapeutics, Inc. has an Innovation Score of 36.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Prometic Biotherapeutics, Inc. focus on?
Prometic Biotherapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 5 patents. The company has filed patents in 4 CPC subclasses total.
Is Prometic Biotherapeutics, Inc.'s patent filing rate increasing or decreasing?
Prometic Biotherapeutics, Inc.'s recent filing velocity is +300% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Prometic Biotherapeutics, Inc.'s patents?
Prometic Biotherapeutics, Inc.'s patents average 21.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Prometic Biotherapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Prometic's 5 grants land it in the top 47% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Prometic ranks #49,611 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.